CONTEXT: Although Crooke's changes in the pituitary corticotrophs were initially described in 1935, the prevalence in which the changes occur in patients with Cushing's syndrome (CS) has not been established. OBJECTIVE: This study aimed to determine the prevalence and assess clinical features associated with the presence or absence of Crooke's changes in a large set of patients with CS. DESIGN: Information from a prospective computer database and retrospective chart review was analyzed. SETTING: The setting was an academic medical center. PATIENTS: Consecutive patients (N = 213) who received surgery with a preoperative diagnosis of Cushing's disease are included. INTERVENTION: The patients received pituitary surgery and specimens obtained underwent pathological analysis. MAIN OUTCOME MEASURE: The presence or absence of Crooke's changes was determined by histopathological analysis of the normal pituitary tissue included with the specimen obtained at surgery. Cortisol production was measured by 24-hour urine cortisol production. RESULTS: Crooke's changes occurred in 144 of 177 patients (81%) with a histologically demonstrated ACTH-staining tumor and in 74% of 213 patients diagnosed with CS who had pituitary surgery. The presence of Crooke's changes correlated with the finding of an ACTH-staining tumor removed at surgery and with the degree of hypercortisolism. Among patients with histologically established ACTH-staining tumors the prevalence of Crooke's changes was particularly high in patients with a 24-h urinary free cortisol (UFC) of at least 4-fold the upper limit of normal, in which 91% of patients had Crooke's changes, compared with 74% of patients whose maximum UFC was less than 4-fold the upper limit of normal (P = .008). CONCLUSIONS: Crooke's changes occur in 75-80% of patients with CS, and depend on the degree of hypercortisolism and individual variability. Almost all patients with UFC at least 4-fold the upper limit of normal have them, whereas with less severe hypercortisolism the expression of Crooke's changes varies from person to person.
CONTEXT: Although Crooke's changes in the pituitary corticotrophs were initially described in 1935, the prevalence in which the changes occur in patients with Cushing's syndrome (CS) has not been established. OBJECTIVE: This study aimed to determine the prevalence and assess clinical features associated with the presence or absence of Crooke's changes in a large set of patients with CS. DESIGN: Information from a prospective computer database and retrospective chart review was analyzed. SETTING: The setting was an academic medical center. PATIENTS: Consecutive patients (N = 213) who received surgery with a preoperative diagnosis of Cushing's disease are included. INTERVENTION: The patients received pituitary surgery and specimens obtained underwent pathological analysis. MAIN OUTCOME MEASURE: The presence or absence of Crooke's changes was determined by histopathological analysis of the normal pituitary tissue included with the specimen obtained at surgery. Cortisol production was measured by 24-hour urine cortisol production. RESULTS:Crooke's changes occurred in 144 of 177 patients (81%) with a histologically demonstrated ACTH-staining tumor and in 74% of 213 patients diagnosed with CS who had pituitary surgery. The presence of Crooke's changes correlated with the finding of an ACTH-staining tumor removed at surgery and with the degree of hypercortisolism. Among patients with histologically established ACTH-staining tumors the prevalence of Crooke's changes was particularly high in patients with a 24-h urinary free cortisol (UFC) of at least 4-fold the upper limit of normal, in which 91% of patients had Crooke's changes, compared with 74% of patients whose maximum UFC was less than 4-fold the upper limit of normal (P = .008). CONCLUSIONS:Crooke's changes occur in 75-80% of patients with CS, and depend on the degree of hypercortisolism and individual variability. Almost all patients with UFC at least 4-fold the upper limit of normal have them, whereas with less severe hypercortisolism the expression of Crooke's changes varies from person to person.
Authors: C Villa; A Vasiljevic; M L Jaffrain-Rea; O Ansorge; S Asioli; V Barresi; L Chinezu; M P Gardiman; A Lania; A M Lapshina; L Poliani; L Reiniger; A Righi; W Saeger; J Soukup; M Theodoropoulou; S Uccella; J Trouillas; F Roncaroli Journal: Virchows Arch Date: 2019-10-02 Impact factor: 4.064
Authors: David P Bray; Rima S Rindler; Reem A Dawoud; Andrew B Boucher; Nelson M Oyesiku Journal: Otolaryngol Clin North Am Date: 2022-03-04 Impact factor: 1.866
Authors: José Miguel Hinojosa-Amaya; César Ernesto Lam-Chung; Daniel Cuevas-Ramos Journal: Front Endocrinol (Lausanne) Date: 2021-04-26 Impact factor: 5.555
Authors: Amit Akirov; Vincent Larouche; Ilan Shimon; Sylvia L Asa; Ozgur Mete; Anna M Sawka; Fred Gentili; Shereen Ezzat Journal: Front Endocrinol (Lausanne) Date: 2021-03-18 Impact factor: 5.555
Authors: Lukas Andereggen; Luigi Mariani; Jürgen Beck; Robert H Andres; Jan Gralla; Markus M Luedi; Joachim Weis; Emanuel Christ Journal: Acta Neurochir (Wien) Date: 2021-04-03 Impact factor: 2.816
Authors: Mario Detomas; Barbara Altieri; Wiebke Schlötelburg; Silke Appenzeller; Sven Schlaffer; Roland Coras; Andreas Schirbel; Vanessa Wild; Matthias Kroiss; Silviu Sbiera; Martin Fassnacht; Timo Deutschbein Journal: Front Endocrinol (Lausanne) Date: 2021-08-20 Impact factor: 5.555
Authors: Regin Jay Mallari; Jai Deep Thakur; Garni Barkhoudarian; Amy Eisenberg; Amanda Rodriguez; Sarah Rettinger; Pejman Cohan; Lynnette Nieman; Daniel F Kelly Journal: J Clin Endocrinol Metab Date: 2022-01-01 Impact factor: 5.958